Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 6/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.39 |
| ▸ | KDM6B | O15054 | 2/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.37 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.37 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.37 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.35 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | HTR6 | P50406 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19652243 | 0.85 | DPP4 (0.41) | ADRA2AKDM4CTRPV1KDM6BDPP4 | |
| SCHEMBL29920509 | 0.82 | ADRA2A (0.38) | ADRA2AKDM4CTRPV1KDM6BNTRK1 | |
| SCHEMBL12269707 | 0.81 | GAA (0.41) | TRPV1MAP3K14 | |
| SCHEMBL28788365 | 0.78 | KDM4C (0.43) | ADRA2AKDM4CTRPV1NTRK1MAPK1 | |
| SCHEMBL31395451 | 0.77 | ADRA2A (0.41) | ADRA2AKDM4C | |
| SCHEMBL29920615 | 0.76 | ADRA2A (0.41) | ADRA2AKDM4CTRPV1KDM6BMAP3K14 | |
| SCHEMBL27830379 | 0.75 | ADRA2A (0.47) | ADRA2AKDM4CTRPV1MAP3K14NTRK1 | |
| SCHEMBL1569617 | 0.74 | KDM4C (0.46) | ADRA2AKDM4C | |
| SCHEMBL30989905 | 0.73 | KDM4C (0.40) | ADRA2AKDM4CKDM6BNTRK1 | |
| SCHEMBL24593571 | 0.72 | ADRA2A (0.50) | ADRA2AKDM4CTRPV1MAP3K14NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170340604-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | BRD4, BRDT, BRD3 | ADRA2A 2340/4885KDM4C 264/4885TRPV1 1781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.